Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.

P Lissoni1, F Brivio, S Pittalis

  • 1Divisione di Radioterapia Oncologica, Hospital of Monza, Italy.

British Journal of Cancer
|November 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

First Evidence for Mixing-Induced CP Violation in B_{s}^{0}→J/ψϕ(1020) Decays in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

Observation of Suppressed Charged-Particle Production in Ultrarelativistic Oxygen-Oxygen Collisions.

Physical review letters·2026
Same author

Measurement of D^{0} Meson Photoproduction in Ultraperipheral Heavy Ion Collisions.

Physical review letters·2026
Same author

Observation of tWZ Production at the CMS Experiment.

Physical review letters·2026
Same author

First Exclusive Reconstruction of the B^{*+}, B^{*0}, and B_{s}^{*0} Mesons and Precise Measurement of Their Masses.

Physical review letters·2026
Same journal

De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.

British journal of cancer·2026
Same journal

Planetary Health Diet Index and breast cancer risk.

British journal of cancer·2026
Same journal

Can national lung cancer screening programs be implemented without exacerbating social disparities?

British journal of cancer·2026
Same journal

Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.

British journal of cancer·2026
Same journal

Circulating metabolite biomarkers associated with prostate cancer risk in Black Americans: findings from the Southern Community Cohort Study.

British journal of cancer·2026
Same journal

Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use.

British journal of cancer·2026
See all related articles

Interleukin-2 (IL-2) therapy rapidly lowers cholesterol levels in cancer patients, normalizing concentrations within 7 days for hypercholesterolemic individuals. This cytokine demonstrates significant cholesterol-lowering activity, impacting metabolic pathways.

Area of Science:

  • Immunology
  • Metabolic research
  • Oncology

Background:

  • Interleukin-2 (IL-2) possesses known immunomodulating and antitumour properties.
  • IL-2 also induces systemic effects on cardiovascular, neuroendocrine, and metabolic systems.
  • The specific impact of IL-2 on cholesterol metabolism requires further investigation.

Purpose of the Study:

  • To evaluate the effects of subcutaneous Interleukin-2 (IL-2) on cholesterol metabolism in advanced cancer patients.
  • To assess changes in total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride levels during IL-2 therapy.
  • To investigate the relationship between IL-2 administration and alterations in conjugated biliary acid levels.

Main Methods:

  • A cohort of 14 advanced cancer patients (10 renal, 4 colon carcinoma) received subcutaneous IL-2.

Related Experiment Videos

  • The treatment regimen involved 1.8 x 10^6 IU/mL twice daily for 5 days/week over 6 weeks.
  • Blood samples were collected at multiple time points before, during, and after IL-2 therapy.

    • Main Results:

    • IL-2 induced a rapid and significant decrease in total cholesterol levels.
    • Cholesterol normalization occurred within 7 days in all hypercholesterolemic patients.
    • The LDL/HDL cholesterol ratio was significantly reduced, accompanied by increased conjugated biliary acid levels.
    • Triglyceride levels showed a non-significant increase during therapy.

    Conclusions:

    • IL-2 demonstrates potent and rapid cholesterol-lowering activity in cancer patients.
    • These findings highlight the physiological role of cytokines, like IL-2, in regulating cholesterol metabolism.
    • IL-2's metabolic effects may offer additional therapeutic insights beyond its immunomodulatory actions.